ASIT Biotech’s H1 results statement included an outline of its preparations for the confirmatory Phase III study of its short-course gp-ASIT+ for grass pollen allergy, including the appointment of a single CRO. ASIT’s H118 operating loss was €5.4m, within which R&D comprised €4.5m. End of June net cash of €13.0m and the July convertible bond issue leave ASIT comfortably funded through 2020 in our model.
27 Sep 2018
ASIT Biotech - Setting the stage for the confirmatory Phase III
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ASIT Biotech - Setting the stage for the confirmatory Phase III
ASIT Biotech’s H1 results statement included an outline of its preparations for the confirmatory Phase III study of its short-course gp-ASIT+ for grass pollen allergy, including the appointment of a single CRO. ASIT’s H118 operating loss was €5.4m, within which R&D comprised €4.5m. End of June net cash of €13.0m and the July convertible bond issue leave ASIT comfortably funded through 2020 in our model.